Overview

  • Product name2,3-Butanedione 2-monoxime (BDM)
  • Description
    Non-selective myosin ATPase inhibitor
  • Alternative names
    • BDM
    • Biacetyl monoxime
    • Diacetyl monoxime
  • Biological descriptionNon-selective myosin ATPase inhibitor (Ki = 5 mM at myosin II). Potent Kv2.1 (DRK1) and L-Type Ca2+ channel inhibitor (Ki and IC50 values are 10.7 nM and 5.8 mM, respectively). Blood-brain barrier permeable. Inhibits muscle contraction.

Properties

    References for 2,3-Butanedione 2-monoxime (BDM) (ab120616)

    This product has been referenced in:
    • Artigas P  et al. 2,3-butanedione monoxime affects cystic fibrosis transmembrane conductance regulator channel function through phosphorylation-dependent and phosphorylation-independent mechanisms: the role of bilayer material properties. Mol Pharmacol 70:2015-26 (2006). Read more (PubMed: 16966478) »
    • Ostap EM 2,3-Butanedione monoxime (BDM) as a myosin inhibitor. J Muscle Res Cell Motil 23:305-8 (2002). Read more (PubMed: 12630704) »
    • Smith PA  et al. Block of ATP-sensitive K+ channels in isolated mouse pancreatic beta-cells by 2,3-butanedione monoxime. Br J Pharmacol 112:143-9 (1994). Read more (PubMed: 8032636) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120616.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"